clinical trial · NCT07863167
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase2·recruiting·n = 660
Non-small Cell Lung Canceradebrelimab + SHR-A2009paclitaxel or pemetrexed combined with carboplatin +adebrelimabadebrelimab + SHR-A2009adebrelimab + SHR-A2009adebrelimabadebeliizumab + SHR-A2009adebeliizumab + SHR-A2009adebeliizumab + platinum-containing double chemotherapy
brief summary
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
started
Oct 30, 2026
primary completion
Dec 30, 2028
completion
Dec 30, 2030
last updated
Nov 18, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol